Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz; Linda M. Henricks; Steven M. Offer; Julia Barbarino; Jan H.M. Schellens; Jesse J. Swen; Teri E. Klein; Howard L. McLeod; Kelly E. Caudle; Robert B. Diasio; Matthias Schwab

doi:10.1002/cpt.911

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Ursula Amstutz, Linda M. Henricks, Steven M. Offer, Julia Barbarino, Jan H.M. Schellens, Jesse J. Swen, Teri E. Klein, Howard L. McLeod, Kelly E. Caudle, Robert B. Diasio, Matthias Schwab

Research output: Contribution to journal › Article › peer-review

157 Scopus citations

Abstract

The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC ^® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

Original language	English (US)
Pages (from-to)	210-216
Number of pages	7
Journal	Clinical pharmacology and therapeutics
Volume	103
Issue number	2
DOIs	https://doi.org/10.1002/cpt.911
State	Published - Feb 2018

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1002/cpt.911

Cite this

Amstutz, U., Henricks, L. M., Offer, S. M., Barbarino, J., Schellens, J. H. M., Swen, J. J., Klein, T. E., McLeod, H. L., Caudle, K. E., Diasio, R. B., & Schwab, M. (2018). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical pharmacology and therapeutics, 103(2), 210-216. https://doi.org/10.1002/cpt.911

Amstutz, U, Henricks, LM, Offer, SM, Barbarino, J, Schellens, JHM, Swen, JJ, Klein, TE, McLeod, HL, Caudle, KE, Diasio, RB & Schwab, M 2018, 'Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update', Clinical pharmacology and therapeutics, vol. 103, no. 2, pp. 210-216. https://doi.org/10.1002/cpt.911

@article{4eeb175e18ed4b40aebc6cd9ac952163,

title = "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update",

abstract = " The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC {\textregistered} ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).",

author = "Ursula Amstutz and Henricks, {Linda M.} and Offer, {Steven M.} and Julia Barbarino and Schellens, {Jan H.M.} and Swen, {Jesse J.} and Klein, {Teri E.} and McLeod, {Howard L.} and Caudle, {Kelly E.} and Diasio, {Robert B.} and Matthias Schwab",

note = "Publisher Copyright: {\textcopyright} 2017 American Society for Clinical Pharmacology and Therapeutics",

year = "2018",

month = feb,

doi = "10.1002/cpt.911",

language = "English (US)",

volume = "103",

pages = "210--216",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

T2 - 2017 Update

AU - Amstutz, Ursula

AU - Henricks, Linda M.

AU - Offer, Steven M.

AU - Barbarino, Julia

AU - Schellens, Jan H.M.

AU - Swen, Jesse J.

AU - Klein, Teri E.

AU - McLeod, Howard L.

AU - Caudle, Kelly E.

AU - Diasio, Robert B.

AU - Schwab, Matthias

PY - 2018/2

Y1 - 2018/2

N2 - The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC ® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

AB - The purpose of this guideline is to provide information for the interpretation of clinical dihydropyrimidine dehydrogenase (DPYD) genotype tests so that the results can be used to guide dosing of fluoropyrimidines (5-fluorouracil and capecitabine). Detailed guidelines for the use of fluoropyrimidines, their clinical pharmacology, as well as analyses of cost-effectiveness are beyond the scope of this document. The Clinical Pharmacogenetics Implementation Consortium (CPIC ® ) guidelines consider the situation of patients for which genotype data are already available (updates available at https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/).

UR - http://www.scopus.com/inward/record.url?scp=85034255321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034255321&partnerID=8YFLogxK

U2 - 10.1002/cpt.911

DO - 10.1002/cpt.911

M3 - Article

C2 - 29152729

AN - SCOPUS:85034255321

SN - 0009-9236

VL - 103

SP - 210

EP - 216

JO - Clinical pharmacology and therapeutics

JF - Clinical pharmacology and therapeutics

IS - 2

ER -

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this